MFA
SLS icon

Millington Financial Advisors’s SELLAS Life Sciences SLS Stock Holding History

Millington Financial Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122K Hold
25,000
– – 0.05% 115
2025
Q4 		$93.3K Buy
+25,000
New +$48.6K 0.04% 115

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Millington Financial Advisors's SLS Position: Q1 2026 in Review

Millington Financial Advisors held its SELLAS Life Sciences (SLS) position steady in Q1 2026 at 25,000 shares worth $122K. The position accounts for 0.05% of the portfolio, ranked #115.

Millington Financial Advisors first reported a position in SLS in Q4 2025 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Millington Financial Advisors held 25,000 shares of SELLAS Life Sciences worth $122K as of Q1 2026.
  • Millington Financial Advisors left its SELLAS Life Sciences share count unchanged in Q1 2026.
  • SELLAS Life Sciences made up 0.05% of Millington Financial Advisors's portfolio in Q1 2026, its #115 holding.
  • Millington Financial Advisors first reported a position in SELLAS Life Sciences in Q4 2025 and has held it in 2 quarters since.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Millington Financial Advisors's 13F filing for Q1 2026, filed 8 May 2026.